Last update June 29, 2022


High Risk

Poorly safe. Evaluate carefully. Use safer alternative or interrupt breastfeeding 3 to 7 T ½ (elimination half-lives). Read the Comment.

Serotonin and Norepinephrine selective re-uptake inhibitor. Used in the treatment of depression. Authorized for treatment of Fibromyalgia in some countries. Oral administration in two daily doses.

Latest update failed to find relevant data on breastfeeding.

According to the manufacturer, it is excreted in breast milk in small amounts. (FDA 2012)

Pharmacokinetic data (low serum protein binding and high bioavailability) indicates that drug excretion into breast milk in significant amount is highly probable. Absorption by the infant is likely to be high as well.

At usual dose it does not induce galactorrhea. (Trenque 2011)

Frequent and potential severe side effects have been found.

Until more published data is known about this drug in relation to breastfeeding, known safer alternatives are preferable, especially during the neonatal period and in the event of prematurity.

See below the information of this related product:

  • Maternal Depression (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)


  • Duloxetine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Paroxetine ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Pregabalin (Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.)
  • Sertraline Hydrochloride ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

N06AX17 is Milnacipran Hydrochloride in ATC Code/s.

Is written in other languages:

N06AX17 is also known as


N06AX17 belongs to these groups or families:


Main tradenames from several countries containing N06AX17 in its composition:


Variable Value Unit
Oral Bioavail. 85 - 90 %
Molecular weight 283 daltons
Protein Binding 13 %
VD 5.5 - 6.8 l/Kg
pKa 9.8 -
Tmax 2 - 4 hours
6 - 8 hours
Theoretical Dose 0.02 - 0.04 mg/Kg/d
Relative Dose 2.8 %


  1. FDA. MIlnacipran (Savella). Drug Summary. 2012 Full text (in our servers)
  2. Trenque T, Herlem E, Auriche P, Dramé M. Serotonin reuptake inhibitors and hyperprolactinaemia: a case/non-case study in the French pharmacovigilance database. Drug Saf. 2011 Abstract
  3. EMeA Preguntas y respuestas sobre la recomendación de denegar la autorización de comercialización de \ Milnacipran EMA 2009
  4. EMeA Questions and answers on the recommendation for the refusal of the marketing authorisation for Milnacipran EMA 2009 Full text (in our servers)
  5. Puozzo C, Panconi E, Deprez D. Pharmacology and pharmacokinetics of milnacipran. Int Clin Psychopharmacol. 2002 Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM